11 May, 2009 – 20:04 | 7 Comments

In an about-face to their stance during the Clinton Administration, leaders of the nation’s healthcare industry have promised to cut prices in response to the Obama Administration’s vow to resolve the healthcare crisis and make health care available to every…

Read the full story »
Diet

Drugs

Lifestyle

Medical Research

Prevention

Home » Drugs, FDA

FDA Approves First New Gout Drug in 40 Years

Submitted by MedHeadlines on 16 February, 2009 – 23:515 Comments

It’s been 40 years since the US Food and Drug Administration (FDA) approved a new drug for treating gout but the new drug, Uloric (febuxostat), has just passed the test, according to Takeda Pharmaceuticals, maker of Uloric.  A daily dose of the drug, taken orally, is recommended for management of chronic hyperuricemia in patients with gout.

Gout, a painful disease affecting the joints, is caused by a build-up of uric acid.  Uloric inhibits the enzyme, xanthine oxidase, thereby minimizing production of uric acid.  This decreased uric acid production lowers the acid level in the body and reduces the pain caused by elevated uric acid levels.

Safety questions were raised in 2005 when Takeda first submitted Uloric for FDA approval.  At that time, Uloric was thought to cause heart problems and death in more patients than allopurinol does.  Allopurinol is the most commonly prescribed drug for gout at this time.

Takeda expanded its study of Uloric, conducting a phase III clinical trial involving even more gout patients than were included in both phase III trials conducted at that time.  The new findings indicate Uloric is no more likely to cause heart disease or death than allopurinol is.  The drug earned its current FDA approval based on these findings, along with the requirement that these safety issues are discussed with the patient.

According to Takeda, Uloric’s most common adverse side effects, as identified during its clinical trials, include abnormalities in liver function tests, joint pain, nausea, and rashes.

Related Products:

5 Comments »

Leave a comment!

Add your comment below, or trackback from your own site. You can also subscribe to these comments via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:
<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.